Figure 7
From: Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists
In vitro effect of tumour necrosis factor antagonists on proliferative responses to recall antigens. The effect of infliximab (Ifx), adalimumab (Ada), and etanercept (Eta) (10 μg/ml) on the proliferation of lymphocytes was determined using the thymidine incorporation assay after 5 days of activation with purified protein derivative (PPD), Candida (Cd), cytomegalovirus (CMV), or Tetanus toxoid (TT). Five patients (3 from group III and 2 from group IV) were tested. Results (mean ± standard error of the mean) are expressed as percentage of controls, corresponding to cells cultured with a control antibody. *p < 0.05 and **p < 0.01 as compared with controls (Wilcoxon test with Bonferroni corrections).